Hydrostat 500 Capsule contains Hydroxyurea 500 mg, an antineoplastic agent primarily used in the management of various hematologic disorders and malignancies. Hydroxyurea acts by inhibiting ribonucleotide reductase, thereby interfering with DNA synthesis and exerting cytotoxic effects on rapidly dividing cells. It is commonly prescribed for the treatment of chronic myeloid leukemia (CML), polycythemia vera, essential thrombocythemia, and sickle cell anemia to reduce the frequency of painful crises. Hydrostat 500 Capsule is administered orally and should be taken under strict medical supervision with dosage adjustments based on clinical response and hematologic parameters. Regular monitoring of blood counts is essential to detect potential myelosuppression, a significant adverse effect. Other side effects may include gastrointestinal disturbances, mucocutaneous reactions, and, rarely, secondary malignancies with long-term use. Caution is advised in patients with renal or hepatic impairment, and it is contraindicated during pregnancy due to teratogenic potential. Patients should be advised to maintain adequate hydration and report any signs of infection or unusual bleeding promptly. Hydrostat 500 Capsule offers a valuable therapeutic option in the management of specific hematologic conditions, improving patient outcomes when used appropriately within established treatment protocols.